# H. Lundbeck A/S clinical trials: 224 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 224 trials with H. Lundbeck A/S as lead sponsor, 9 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by H. Lundbeck A/S: 224 rows for $11.20, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/h-lundbeck-a-s

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 224
- Recruiting or not yet: 9
- Read on: November 19, 2026

## Trials

The 25 newest of 224, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 5, 2026 | NCT07859293 | An Extension Trial of Asedebart in Participants With Congenital Adrenal Hyperplasia | H. Lundbeck A/S | Phase 2 | Not yet recruiting | Adrenal Hyperplasia, Congenital | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07859293) |
| August 20, 2026 | NCT07775261 | A Trial of Lu AH69593 in Healthy Participants | H. Lundbeck A/S | Phase 1 | Recruiting | Healthy Participants | 46 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07775261) |
| May 29, 2026 | NCT07613710 | A Trial to Test the Safety and Tolerability of Lu AH69593 in Adults That Are Healthy or Have Narcolepsy | H. Lundbeck A/S | Phase 1 | Recruiting | Narcolepsy | 104 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07613710) |
| April 7, 2026 | NCT07514858 | A Trial Investigating Lu AF28996 in Adults With Parkinson's Disease Who Have Motor Fluctuations | H. Lundbeck A/S | Phase 2 | Recruiting | Parkinson's Disease | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07514858) |
| April 7, 2026 | NCT07513441 | A Trial of Lu AF28996 in Participants With Parkinson's Disease (PD) | H. Lundbeck A/S | Phase 1 | Recruiting | Parkinson Disease | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07513441) |
| November 26, 2024 | NCT06706622 | A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) | H. Lundbeck A/S | Phase 3 | Active not recruiting | Multiple System Atrophy | 401 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06706622) |
| November 22, 2024 | NCT06701526 | A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications | H. Lundbeck A/S | Phase 4 | Completed | Migraine | 164 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06701526) |
| August 29, 2024 | NCT06578585 | A Trial Investigating Lu AG09222 With Ubrogepant in Participants With Migraine | H. Lundbeck A/S | Phase 1 | Completed | Migraine | 43 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06578585) |
| August 16, 2024 | NCT06557850 | A Trial Investigating Lu AG22515 in Adult Participants With Moderate-to-Severe Thyroid Eye Disease | H. Lundbeck A/S | Phase 1 | Active not recruiting | Thyroid Eye Disease | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06557850) |
| June 24, 2024 | NCT06471829 | A Trial of Lu AG13909 in Adult Participants With Cushing's Disease | H. Lundbeck A/S | Phase 2 | Active not recruiting | Cushing's Disease | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06471829) |
| March 29, 2024 | NCT06337110 | A Study Investigating the Movement of Lu AF28996 Into, Through, and Out of the Body of Healthy Men | H. Lundbeck A/S | Phase 1 | Completed | Healthy Participants | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06337110) |
| March 21, 2024 | NCT06323928 | A Dose-finding Trial With Lu-AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments | H. Lundbeck A/S | Phase 2 | Completed | Migraine | 874 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06323928) |
| February 26, 2024 | NCT06277609 | A Trial Investigating Lu AF28996 in Healthy Adult Participants | H. Lundbeck A/S | Phase 1 | Completed | Healthy Participants | 22 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06277609) |
| February 14, 2024 | NCT06258720 | A Trial Investigating Lu AF82422 in Healthy Chinese and Caucasian Adults | H. Lundbeck A/S | Phase 1 | Completed | Healthy Participants | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06258720) |
| October 11, 2023 | NCT06077786 | A Trial Investigating the Pain-relieving Properties of Lu AG06474 in Healthy Adult Participants | H. Lundbeck A/S | Phase 1 | Completed | Healthy Participants | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06077786) |
| August 22, 2023 | NCT06004180 | A Trial Investigating Lu AF28996 in Adult Japanese Participants With Parkinson's Disease (PD) | H. Lundbeck A/S | Phase 1 | Completed | Parkinson Disease | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06004180) |
| July 13, 2023 | NCT05943327 | A Study Investigating Lu AG06474 in Healthy Young Participants | H. Lundbeck A/S | Phase 1 | Terminated | Healthy Participants | 56 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05943327) |
| June 9, 2023 | NCT05897320 | A Study of Eptinezumab in Pediatric Participants With Episodic Migraine | H. Lundbeck A/S | Phase 3 | Recruiting | Episodic Migraine | 315 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05897320) |
| January 3, 2023 | NCT05669950 | A Trial of Lu AG13909 in Participants With Congenital Adrenal Hyperplasia | H. Lundbeck A/S | Phase 1/2 | Recruiting | Congenital Adrenal Hyperplasia | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05669950) |
| July 12, 2022 | NCT05453058 | Observational Study in Multiple System Atrophy | H. Lundbeck A/S | Observational | Active not recruiting | Multiple System Atrophy | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05453058) |
| July 11, 2022 | NCT05452239 | A Study of Eptinezumab in Participants With Migraine and Medication Overuse Headache | H. Lundbeck A/S | Phase 4 | Completed | Migraine, Medication Overuse Headache | 608 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05452239) |
| April 11, 2022 | NCT05320302 | A Brain Imaging PET Study of \[11C\]-Lu AF88370 in Healthy Adult Male Participants | H. Lundbeck A/S | Phase 1 | Completed | Healthy Participants | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05320302) |
| April 1, 2022 | NCT05306366 | A Brain Imaging PET Study of \[11C\]-Lu AF90103 in Healthy Adult Male Participants | H. Lundbeck A/S | Phase 1 | Completed | Healthy Young Men | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05306366) |
| March 31, 2022 | NCT05304910 | A Study Investigating the Movement of Lu AG09222 Into, Through, and Out of the Body of Healthy Caucasian, Chinese, and Japanese Participants | H. Lundbeck A/S | Phase 1 | Completed | Migraine | 52 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05304910) |
| March 17, 2022 | NCT05284019 | Real World Effectiveness of Eptinezumab in Participants With Migraine | H. Lundbeck A/S | Phase 4 | Terminated | Migraine | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05284019) |

## By phase

| Phase | Trials |
| --- | --- |
| Early phase 1 | 1 |
| Phase 1 | 92 |
| Phase 1/2 | 1 |
| Phase 2 | 27 |
| Phase 3 | 82 |
| Phase 4 | 18 |
| Observational | 3 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 168 |
| Terminated | 38 |
| Recruiting | 8 |
| Active not recruiting | 5 |
| Withdrawn | 4 |
| Not yet recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Depressive Disorder, Major | 34 |
| Schizophrenia | 28 |
| Migraine Disorders | 15 |
| Sleep Initiation and Maintenance Disorders | 15 |
| Alzheimer Disease | 15 |
| Parkinson Disease | 14 |
| Depression | 9 |
| Alcoholism | 6 |
| Multiple System Atrophy | 4 |
| Ischemic Stroke | 4 |
| Mental Disorders | 4 |
| Alcohol-Related Disorders | 3 |
| Renal Insufficiency | 3 |
| Depressive Disorder | 3 |
| Headache Disorders, Secondary | 2 |
| Anxiety Disorders | 2 |
| Cluster Headache | 2 |
| Epilepsies, Myoclonic | 2 |
| Neurodegenerative Diseases | 2 |
| Pure Autonomic Failure | 2 |
| Stroke | 2 |
| Bipolar Disorder | 2 |
| Mania | 2 |
| Stress Disorders, Post-Traumatic | 2 |
| Mood Disorders | 2 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Acupuncture clinics in the United States](https://specstream.ai/data/businesses/acupuncture-clinics/united-states)
- [Private schools in the United States](https://specstream.ai/data/businesses/private-schools/united-states)
- [Hydro jetting companies in the United States](https://specstream.ai/data/businesses/hydro-jetting-companies/united-states)
- [Comfort food restaurants in the United States](https://specstream.ai/data/businesses/comfort-food-restaurants/united-states)
- [Water purification companies in the United States](https://specstream.ai/data/businesses/water-purification-companies/united-states)
- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
